Viral vector for induction of CTL (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Viral vector for induction of CTL (Meeting abstract).

Specific Immunotherapy of Cancer with Vaccines. January 21-24, 1993, Washington, DC, A34, 1993.. Unique Identifier : AIDSLINE ICDB/94698150
Paoletti E; Virogenetics Corp., Rensselaer Technology Park, Troy, NY

Abstract: Two unique poxvirus vectors are available for expression of foreign genes. NYVAC is an attenuated strain of the Copenhagen vaccinia smallpox vaccine. Attenuation was effected by the precise deletion of 18 open reading frames associated with virulence or host range. NYVAC is safe by numerous tests including intracranial inoculation into newborn mice. No disseminated infection was observed in severely immunocompromised animals. ALVAC is an avipoxvirus, canary-pox. Avipoxviruses are restricted for productive viral replication to avian species and in mammals provide uniquely safe immunizing vehicles. Upon inoculation in mammalian species, including man, ALVAC elicits cellular, humoral and protective immunity. One of the features inherent within this vector approach is the intracellular synthesis of antigens which allows for the association of peptides with MHC-1. Cellular immune responses including specific induction of CD8+ CTL responses have been demonstrated with human immunodeficiency virus, cytomegalovirus and rabiesvirus proteins in laboratory animal model systems as well as in man. These vectors are also useful in the ex vivo expansion of CD8+ CTLs from HIV seropositives. The utility of these vectors for the expression of tumor-associated antigens in conjunction with specific cytokines is just now beginning to be evaluated.

Keywords: Animal Antibody Formation *Genetic Vectors HIV Infections/IMMUNOLOGY HIV Seropositivity/IMMUNOLOGY Immunity, Cellular *Immunotherapy Mice Poxviridae/GENETICS/*IMMUNOLOGY T-Lymphocytes, Cytotoxic/*IMMUNOLOGY Vaccinia Virus/*IMMUNOLOGY/PHYSIOLOGY Virus Replication ABSTRACT
940630
M9460921

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .